EMMA
Endometrial Microbiome Metagenomic Analysis
by Igenomix

ALICE
Analysis of Infectious Chronic Endometritis
by Igenomix

Igenomix®
PART OF VITROLIFE GROUP

Since EMMA & ALICE launched in 2018, Igenomix has analyzed more than 70,000 clinical samples. All bacteria included are clinically relevant and identified at the species level for a more targeted antibiotic treatment.

www.igenomix.com

		ANALYZES
EMMA Endometrial Microbiome Metagenomic Analysis	**Endometrial Microbiome Metagenomic Analysis** EMMA analyzes the microbiome for a better reproductive prognosis.	**Chronic endometritis + Bacterial flora**
ALICE Analysis of Infectious Chronic Endometritis	**Analysis of Infectious Chronic Endometritis** ALICE detects the bacteria causing chronic endometritis and recommends the adequate treatment.	**Chronic endometritis**

v. 2023

EMMA
Endometrial Microbiome Metagenomic Analysis
by Igenomix

ALICE
Analysis of Infectious Chronic Endometritis
by Igenomix

Igenomix®
PART OF VITROLIFE GROUP

Independent study demonstrated improved clinical outcomes with the EMMA test

To aim of this study was to determine if analysis of the endometrial microbiome with the EMMA test and its recommended treatments have positive impacts on the clinical outcomes in patients with recurrent implantation failure (RIF).

N= 195 RIF women undergoing IVF

Primary outcome= cumulative pregnancy rate after two additional FETs



Iwami et al., 2023

- 1 in 4 patients needed antibiotics to treat a pathogen detected on the EMMA test
- 90% of the antibiotics administered were not broad spectrum, and tailored to the specific pathogens detected
- Patients in the EMMA Test & Treat Group had statistically significant improved clinical outcomes compared with the Control Group

www.igenomix.com